Updates

Tweets by @CellCentric

All our updates and events through tweets

Great to have many of the core team together; working with our partner clinicians, hospitals, consultants and CROs, to advance inobrodib, our pioneering p300/CBP inhibitor. pic.twitter.com/FS0xWo7zoM

Our clinical development leadership at ASCO. Pioneering p300/CBP inhibition to treat specific cancers. Inobrodib now in Phase II. pic.twitter.com/StoCgrcCvN

CellCentric’s clinical & scientific leadership will be as ASCO 2022. We continue to advance our pioneering p300/CBP inhibitor to treat specific cancers. #ASCO22 pic.twitter.com/SciCvWzilS

Stay up to date with CellCentric and follow us on twitter

Follow us

It’s international clinical trials day. Inobrodib is in Phase II to treat specific cancers in the UK, US and EU. Thank you patients, clinicians, clin ops team! pic.twitter.com/kHwD7bDV2Z

Proud to be a recent addition to the ACS BrightEdge investment family, aligned on the mission to defeat cancer. Latest report: brightedgefund.org/system/uploads… pic.twitter.com/3tqUCk4ek5

CellCentric at LSX next week. Fuelling the progress of inobrodib, our pioneering p300/CBP inhibitor to treat people with cancer. @LSXLeaders pic.twitter.com/x4uBPZkFY9